Vaccine partners pledge to give to COVAX

28 October 2020

Franco-British pairing Sanofi (Euronext: SAN) and GlaxoSmithKline (LSE: GSK) have made a move for the global good by agreeing to support COVAX with 200 million doses of their adjuvanted, recombinant protein-based COVID-19 vaccine candidate.

The COVAX Facility, supported by governments, global health organizations, businesses and philanthropic organizations, is led by Gavi and aims to secure successful and equitable access to COVID-19 vaccines worldwide.

"This has the potential to be a significant contribution to the global fight against COVID-19"Thomas Triomphe, executive vice president and global head of Sanofi Pasteur, said: “To address a global health crisis of this magnitude, it takes unique partnerships. The commitment we are announcing today for the COVAX Facility can help us together stand a better chance of bringing the pandemic under control.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK